// App-Quantinova.ai

BSH2020‐EP‐031 : Updated audit of the use of pegylated interferon in patients with myeloproliferative neoplasms. Are patients maintained on less frequent dosing than once weekly?

Researchers

Presenter

  • C. Loughran

Principal Investigators

  • F. Wadelin

  • R. Fisken

  • A. Thompson

Medical Centers

  • Pharmacy

  • Oncology, Nottingham University Hospital, Nottingham, UK

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Polycythaemia vera

  • Myelofibrosis

Biomarkers

  • Interferon-alpha

  • Janus kinase

Drug/Treatment

  • Hydroxycarbamide

  • Interferon alpha

  • Interferon

  • Roferon A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved